Diplomat Pharmacy, Inc. (NYSE:DPLO)‘s stock had its “buy” rating reissued by equities researchers at Robert W. Baird in a report released on Sunday. They currently have a $20.00 target price on the stock. Robert W. Baird’s target price would indicate a potential upside of 1.63% from the stock’s current price.

A number of other equities analysts also recently issued reports on the stock. BidaskClub raised shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Friday. TheStreet raised shares of Diplomat Pharmacy from a “d+” rating to a “c-” rating in a report on Thursday, August 10th. Zacks Investment Research raised shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. Needham & Company LLC assumed coverage on shares of Diplomat Pharmacy in a report on Friday, July 21st. They issued a “buy” rating and a $19.75 price objective on the stock. Finally, Bank of America Corporation raised their price objective on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the stock a “neutral” rating in a report on Thursday, May 25th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. Diplomat Pharmacy has a consensus rating of “Hold” and an average target price of $18.16.

Shares of Diplomat Pharmacy (DPLO) opened at 19.68 on Friday. The company has a market cap of $1.34 billion, a price-to-earnings ratio of 107.54 and a beta of 0.65. The stock has a 50 day moving average of $16.70 and a 200 day moving average of $16.22. Diplomat Pharmacy has a 52-week low of $12.25 and a 52-week high of $31.33.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, August 7th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.10. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 earnings per share. On average, equities research analysts expect that Diplomat Pharmacy will post $0.75 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/17/diplomat-pharmacy-inc-dplo-given-buy-rating-at-robert-w-baird.html.

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in Diplomat Pharmacy by 73.1% during the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after purchasing an additional 3,056 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in Diplomat Pharmacy by 80.0% during the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after purchasing an additional 3,833 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Diplomat Pharmacy by 13.8% during the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock valued at $142,000 after purchasing an additional 1,073 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in Diplomat Pharmacy during the first quarter valued at approximately $160,000. 69.89% of the stock is currently owned by institutional investors and hedge funds.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.